Comparative Analysis of Daprostat and Traditional Anemia Treatment Drugs

Daprodustat (Daprodustat) is a new drug for the treatment of anemia. Its mechanism is significantly different from traditional anemia treatment drugs such as erythropoietin (ESA) drugs, and it represents a new direction in the treatment of anemia. Traditional anemia treatments mainly rely on ESA drugs and iron supplements. ESA drugs work by directly stimulating the bone marrow to produce red blood cells and are usually given by injection. Iron supplements are used to supplement the iron that is lacking in the body to ensure the normal production of red blood cells.

Compared with these traditional drugs, dapoxostat simulates a hypoxic state by inhibiting hypoxia-inducible factor prolyl hydroxylase (HIF-PH), thereby activating the natural mechanism of erythropoiesis. Specifically, dapoprimostat promotes bone marrow red blood cell production by increasing endogenous erythropoietin (EPO) levels. This mechanism makes dapostat an oral drug, which has obvious advantages compared with injected ESA drugs, especially in terms of patient compliance. Oral administration is convenient and needle-free, especially suitable for patients with chronic kidney disease who require long-term treatment.

In contrast, traditional Although ESA drugs can quickly increase the number of red blood cells, because they directly act on the bone marrow, they may cause more side effects, especially adverse reactions such as high blood pressure and thrombosis. Especially for some high-risk groups, the side effects of ESA drugs often make doctors need to be more cautious during their use. In addition, the use of ESA drugs requires injection, and patient compliance is poor. Long-term use may cause discontinuous treatment.

Another traditional method of treating anemia is iron supplements, which are mainly used to treat iron deficiency anemia. However, in patients with chronic kidney disease, iron absorption and utilization may be problematic due to the chronic course of the disease and decreased renal function, so the effectiveness of iron alone in treating anemia is often limited. On the contrary, daprostat can indirectly solve the anemia problem by promoting the production of endogenous EPO. Even if the patient's iron reserves are insufficient, it can still effectively improve the anemia state.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat